Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy

Blood

Volumn 87, Issue 10, 1996, Pages 4076-4081

  Negrin, Robert S ^a   Stein, Richard ^b   Doherty, Kathleen ^b   Cornwall, Jill ^b   Vardiman, James ^b   Krantz, Sanford ^b   Greenberg, Peter L ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; APLASTIC ANEMIA; ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; FEMALE; HISTOLOGY; HUMAN; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PRELEUKEMIA; PRIORITY JOURNAL; RETICULOCYTE COUNT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0029940725     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4076.bloodjournal87104076     Document Type: Article

References (33)

1. Block M, Jacobson LO, Bethard WF: Preleukemic acute human leukemia. JAMA 152:1018, 1953
2. Greenberg PL: The smoldering myeloid leukemic states: Clinical and biologic features. Blood 61:1035, 1983
3. Pierre RV: Preleukemic states. Semin Hematol 11:73, 1974
4. Tricot G, Mecucci C, Van den Berghe H: Evolution of the myelodysplastic syndromes. Br J Haematol 63:609, 1986
5. Mertelsmann R, Tzvi Thaler H, To L, Gee TS, McKenzie S, Schauer P, Friedman A, Arlin Z, Cirrincione C, Clarkson B: Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773, 1980
6. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sanders JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677, 1993
7. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545, 1987
8. Ganser A, Volkers B, Greher J, Ottman F, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. A phase I/II trial. Blood 73:31, 1989
9. Antin JH, Smith BR, Holmes W, Rosenthal DS: Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72:705, 1988
10. Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A: Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics and hematological effects. J Clin Oncol 7:629, 1989
11. Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I/II trial. Ann Intern Med 110:976, 1989
12. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36, 1990
13. Yoshida Y, Hirashima K, Asano S, Takaku F: A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78:378, 1991
14. Ganser A, Seipelt G, Lindemann A, Ottman OG, Falk S, Eder M, Herrmann F, Becher R, Hofflen K, Buchner T, Klausmann M, Frisch J, Schulz G, Mertlelsmann R, Hoelzer D: Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455, 1990
15. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241, 1991
16. Schuster MW, Thompson JA, Larson R, Allen SL, O'Laughlin R, Israel R, Fefer A: Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor versus observation in patients with myelodysplastic syndrome or aplastic anemia. Proc Am Soc Clin Oncol 9:205a, 1990 (abstr)
17. Greenberg P, Taylor K, Larson R, Koeffler P, Negrin RS, Saba H, Ganser A, Jakubowski A, Gabrilove J, Mufti G, Cruz J, Hammond W, Broudy V, Langley GR, Keating A, Vardiman J, Lamborn K, Brown S: Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes. Blood 82:196a, 1993 (abstr, suppl 1)
18. Bessho M, Jinnai I, Matsuda A: Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 8:445, 1990
19. Stebler C, Tichelli A, Dazzi H, Gratwohl A, Nissen C, Speck B: High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: A pilot study. Exp Hematol 18:1204, 1990
20. Stein RS, Abels RI, Krantz SB: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78:1658, 1991
21. Hellstrom E: Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67, 1995
22. Schouten HC, Vellenga E, van Rhenen DS, de Wolf JTM, Coppens PJW, Bilijham GH: Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5:432, 1991
23. van Kamp H, Prinsze-Postema TC, Kluin PM, Den Ottolander GJ, Beverstock GC, Willemze R, Fibbe WE: Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 78:488, 1991
24. Bowen D, Culligan D, Jacobs A: The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77:419, 1991
25. Rafanelli D, Grossi A, Longo G, Vannucchi AM, Bacci P, Ferrini PR: Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 6:323, 1992
26. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L: The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831, 1995
27. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Weite K: Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 232:61, 1986
28. Greenberg PL, Negrin RS, Ginzton N: G-CSF synergizes with erythropoeitin (EPO) for enhancing erythroid colony-formation (BFU-E) in myelodysplastic syndromes (MDS). Blood 78:38a, 1991 (abstr, suppl 1)
29. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg P: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737, 1993
30. Hellstrom-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I, Ost A: A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221, 1993
31. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
33. Eshbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158, 1989